Literature DB >> 26290375

No effect of albumin infusion on the prevention of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.

Oliviero Riggio1,2, Silvia Nardelli3, Chiara Pasquale3, Ilaria Pentassuglio3, Stefania Gioia3, Eugenia Onori3, Camilla Frieri3, Filippo Maria Salvatori3, Manuela Merli3.   

Abstract

Hepatic encephalopathy (HE) is a major problem in patients submitted to TIPS. Previous studies identified low albumin as a factor associated to post-TIPS HE. In cirrhotics with diuretic-induced HE and hypovolemia, albumin infusion reduced plasma ammonia and improved HE. Our aim was to evaluate if the incidence of overt HE (grade II or more according to WH) and the modifications of venous blood ammonia and psychometric tests during the first month after TIPS can be prevented by albumin infusion. Twenty-three patients consecutively submitted to TIPS were enrolled and treated with 1 g/Kg BW of albumin for the first 2 days after TIPS followed by 0,5 g/Kg BW at day 4th and 7th and then once a week for 3 weeks. Forty-five patients included in a previous RCT (Riggio et al. 2010) followed with the same protocol and submitted to no pharmacological treatment for the prevention of HE, were used as historical controls. No differences in the incidence of overt HE were observed between the group of patients treated with albumin and historical controls during the first month (34 vs 31 %) or during the follow-up (39 vs 48 %). Two patients in the albumin group and three in historical controls needed the reduction of the stent diameter for persistent HE. Venous blood ammonia levels and psychometric tests were also similarly modified in the two groups. Survival was also similar. Albumin infusion has not a role in the prevention of post-TIPS HE.

Entities:  

Keywords:  Albumin; Hepatic encephalopathy; Liver cirrhosis; TIPS

Mesh:

Substances:

Year:  2015        PMID: 26290375     DOI: 10.1007/s11011-015-9713-x

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  38 in total

1.  Two-year outcome following transjugular intrahepatic portosystemic shunt for variceal bleeding: results in 90 patients.

Authors:  J M LaBerge; K A Somberg; J R Lake; R L Gordon; R K Kerlan; N L Ascher; J P Roberts; M M Simor; C A Doherty; J Hahn
Journal:  Gastroenterology       Date:  1995-04       Impact factor: 22.682

2.  Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding.

Authors:  M Rössle; P Deibert; K Haag; A Ochs; M Olschewski; V Siegerstetter; K H Hauenstein; R Geiger; C Stiepak; W Keller; H E Blum
Journal:  Lancet       Date:  1997-04-12       Impact factor: 79.321

3.  Development of stenoses in transjugular intrahepatic portosystemic shunts.

Authors:  G K Nazarian; H Ferral; W R Castañeda-Zúñiga; H Bjarnason; M C Foshager; J M Rank; C A Anderson; G J Rengel; M E Herman; D W Hunter
Journal:  Radiology       Date:  1994-07       Impact factor: 11.105

4.  Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study.

Authors:  O Riggio; A Masini; C Efrati; F Nicolao; S Angeloni; Filippo M Salvatori; M Bezzi; Adolfo F Attili; M Merli
Journal:  J Hepatol       Date:  2005-05       Impact factor: 25.083

5.  Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations.

Authors:  W Nolte; J Wiltfang; C Schindler; H Münke; K Unterberg; U Zumhasch; H R Figulla; G Werner; H Hartmann; G Ramadori
Journal:  Hepatology       Date:  1998-11       Impact factor: 17.425

6.  Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study.

Authors:  Macarena Simón-Talero; Rita García-Martínez; Maria Torrens; Salvador Augustin; Susana Gómez; Gustavo Pereira; Mónica Guevara; Pere Ginés; Germán Soriano; Eva Román; Jordi Sánchez-Delgado; Roser Ferrer; Juan C Nieto; Pilar Sunyé; Inma Fuentes; Rafael Esteban; Juan Córdoba
Journal:  J Hepatol       Date:  2013-07-19       Impact factor: 25.083

7.  Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study.

Authors:  A J Sanyal; A M Freedman; M L Shiffman; P P Purdum; V A Luketic; A K Cheatham
Journal:  Hepatology       Date:  1994-07       Impact factor: 17.425

8.  Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage.

Authors:  J Cabrera; M Maynar; R Granados; E Gorriz; R Reyes; J M Pulido-Duque; J L Rodriguez SanRoman; C Guerra; D Kravetz
Journal:  Gastroenterology       Date:  1996-03       Impact factor: 22.682

9.  Polytetrafluoroethylene-covered stent grafts for TIPS procedure: 1-year patency and clinical results.

Authors:  Stefania Angeloni; Manuela Merli; Filippo Maria Salvatori; Adriano De Santis; Fabrizio Fanelli; Daniela Pepino; Adolfo Francesco Attili; Plinio Rossi; Oliviero Riggio
Journal:  Am J Gastroenterol       Date:  2004-02       Impact factor: 10.864

10.  Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Incidence and risk factors.

Authors:  O Riggio; M Merlli; G Pedretti; R Servi; P Meddi; R Lionetti; P Rossi; M Bezzi; F Salvatori; U Ugolotti; F Fiaccadori; L Capocaccia
Journal:  Dig Dis Sci       Date:  1996-03       Impact factor: 3.199

View more
  8 in total

1.  Cognitive Impairment Predicts The Occurrence Of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt.

Authors:  Silvia Nardelli; Stefania Gioia; Chiara Pasquale; Ilaria Pentassuglio; Alessio Farcomeni; Manuela Merli; Filippo Maria Salvatori; Leandra Nikolli; Sabrina Torrisi; Francesca Greco; Valeria Nicoletti; Oliviero Riggio
Journal:  Am J Gastroenterol       Date:  2016-03-01       Impact factor: 10.864

2.  Albumin therapy for hepatic encephalopathy: current evidence and controversies.

Authors:  Yu Jun Wong; Jing Hong Loo
Journal:  Metab Brain Dis       Date:  2022-05-26       Impact factor: 3.584

3.  CT-based radiomics model for preoperative prediction of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.

Authors:  Sihang Cheng; Xiang Yu; Xinyue Chen; Zhengyu Jin; Huadan Xue; Zhiwei Wang; Ping Xie
Journal:  Br J Radiol       Date:  2022-01-31       Impact factor: 3.629

4.  AISF-SIMTI position paper: the appropriate use of albumin in patients with liver cirrhosis.

Authors:  Paolo Caraceni; Paolo Angeli; Daniele Prati; Mauro Bernardi; Giancarlo M Liumbruno; Francesco Bennardello; Pierluigi Piccoli; Claudio Velati
Journal:  Blood Transfus       Date:  2016-01       Impact factor: 3.443

5.  Albumin infusion may decrease the incidence and severity of overt hepatic encephalopathy in liver cirrhosis.

Authors:  Zhaohui Bai; Mauro Bernardi; Eric M Yoshida; Hongyu Li; Xiaozhong Guo; Nahum Méndez-Sánchez; Yingying Li; Ran Wang; Jiao Deng; Xingshun Qi
Journal:  Aging (Albany NY)       Date:  2019-10-08       Impact factor: 5.682

Review 6.  The Direct Contribution of Astrocytes and Microglia to the Pathogenesis of Hepatic Encephalopathy.

Authors:  Victoria Jaeger; Sharon DeMorrow; Matthew McMillin
Journal:  J Clin Transl Hepatol       Date:  2019-11-13

Review 7.  Albumin administration in patients with cirrhosis: Current role and novel perspectives.

Authors:  Ângelo Zambam de Mattos; Douglas Alano Simonetto; Carlos Terra; Alberto Queiroz Farias; Paulo Lisboa Bittencourt; Tales Henrique Soares Pase; Marlon Rubini Toazza; Angelo Alves de Mattos
Journal:  World J Gastroenterol       Date:  2022-09-07       Impact factor: 5.374

Review 8.  Hepatic encephalopathy: current challenges and future prospects.

Authors:  Mirashini Swaminathan; Mark Alexander Ellul; Timothy Js Cross
Journal:  Hepat Med       Date:  2018-03-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.